MBX Biosciences is trading at $53.99 (-10.48%) as the stock faces a sharp selloff driven by broader weakness in the biotechnology industry.
- The move appears to be a continuation of recent volatility, with no new company-specific catalysts or news confirmed to justify the decline.
- The broader biotech sector is also under pressure, with the XBI down 2.45% as investors engage in profit-taking following a strong recent rally.